Lenalidomide plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia (AML) with recurrent genetic abnormalities- AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM

ConclusionThe high ORR and reasonable duration of response could allow for potentially curative alloHCT in these high-risk AML patients, and this initial data suggests that lenalidomide plus HMA is a promising approach for patients with AML with inv(3).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 9 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Elizabeth Lyden, Andrea Lee, Joel Michalski, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj BhattAbstractBackgroundThe role of obesity in prognosis of acute myeloid leukemia(AML) is debatable. Our retrospective study aimed to determine the effect of obesity on overall survival(OS) in AML.MethodsAML patients diagnosed at University of Nebraska Medical Center were divided into 3-groups based on body mass index (BMI): normal(18.5-25kg/m2) or underweight(
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Kim De Veirman AXL belongs to the TAM (TYRO3, AXL, and MERTK) receptor family, a unique subfamily of the receptor tyrosine kinases. Their common ligand is growth arrest-specific protein 6 (GAS6). The GAS6/TAM signaling pathway regulates many important cell processes and plays an essential role in immunity, hemostasis, and erythropoiesis. In cancer, AXL overexpression and activation has been associated with cell proliferation, chemotherapy resistance, tumor angiogenesis, invasion, and metastasis; and has been correlated with a poor prognosis. In hematological malignancies, the expression and function of AXL is highly...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSION: All tested biosimilars demonstrated similar effectiveness and safety profiles in patients with hematological tumors undergoing PBSC mobilization; therefore, they can be used interchangeably. PMID: 31663634 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Clin Apher Source Type: research
ConclusionOur study did not find a statistically significant difference in overall response rates, or survival outcome measures in patients with AML and indeterminate day 14 bone marrow receiving re-induction or not. Our findings question the utility of immediate re-induction chemotherapy and raise concern for over treatment in this patient population. Larger studies investigating similar outcomes are warranted to validate these clinical findings.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study aimed to analyze the role of postoperative treatment for BC in the development of subsequent HM. Using the French National Health Data System, we examined the HM risks in patients diagnosed with an incident primary breast cancer between 2007 and 2015, who underwent surgery as first-line treatment for BC. Main outcomes were acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), multiple myeloma (MM), Hodgkin’s lymphoma or non-Hodgkin’s lymphoma (HL/NHL), and acute lymphoblastic leukemia or lymphocytic lymphoma (ALL/LL). Analyses were censored at HM o...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Acute myeloid leukemia (AML) is a heterogeneous clonal hematopoietic neoplasm. The cytogenetic changes associated with AML impact response rate and survival, and is one of the most important independent prognostic factors. AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM accounts for 1-2% of all forms of AML, and is associated with a younger age at diagnosis, poor response to standard induction chemotherapy, and very poor long-term prognosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
The benefit of immediate re-induction chemotherapy in patients with indeterminate day 14 bone marrow results ( ≤ 20% cellularity and 5%-20% blasts) remains unclear. Our retrospective analysis compared 25 patients receiving immediate re-induction to 25 patients undergoing observation for indeterminate day 14 results. We did not find a statistically significant difference in overall response rates, or surviv al outcome measures between both groups. Our findings question the utility of immediate re-induction chemotherapy and raise concern for over treatment in this patient population.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Acute myeloid leukemia with GATA2, MECOM has had a poor response to standard induction chemotherapy regimens. We retrospectively compared the data from patients who had received lenalidomide plus a hypomethylating agent with those who had received standard induction therapy. The overall response rate was greater for the patients who had received lenalidomide plus a hypomethylating agent compared with standard induction, suggesting a promising approach for patients with AML with GATA2, MECOM.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackgroundThe optimal the conditioning regimens for allogeneic hematopoietic stem-cell transplantation, especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1562 myeloablative conditioning and 2693 nonmyeloablative conditioning groups, the ove...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Rafiye Ciftciler, Haluk Demiroglu, Ibrahim Celalettin Haznedaroglu, Nilgun Sayınalp, Salih Aksu, Osman Ozcebe, Hakan Goker, Muruvvet Seda Aydın, Yahya BuyukasıkAbstractBackgroundThe majority of patients with acute myeloid leukemia (AML) receive intensive induction chemotherapy for obtaining a complete remission (CR). Despite consolidation chemotherapy and advances in allogeneic hematopoietic stem cell transplantation, most of these patients finally relapse and die from AML. The aim of this study is to determine the ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Genetics | Leukemia | Lymphoma | Myeloma | Revlimid | Study